AdvanCell Closes A$18M Series B Funding Led by Morningside
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and delighted that we will continue our rapid growth with the support of our shareholders. We have had a long-term relationship with our lead investor, Morningside, and are excited to come closer still to our goal to 'Change the Course of Cancer Treatment.'”
Targeted Alpha Therapies represent the most exciting opportunity to treat currently untreatable cancers. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell. AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply. AdvanCell was established to solve this problem.
AdvanCell’s ability to produce isotope on-demand and at scale, and its in-house radiopharmaceutical manufacturing expertise positions AdvanCell to play a leading role in this rapidly growing market. With additional support from NSW Health Medical Devices Fund and the Federal government’s Research & Development Tax Incentive, AdvanCell has developed a world-first scalable manufacturing platform to produce alpha-emitting isotopes for research, pre-clinical and clinical use and to advance its own and its partners' radiopharmaceutical products.
Anthony Aiudi from Morningside commented, “AdvanCell is leveraging its ability to make alpha isotopes at scale and in clinically useful amounts along with its radiochemistry expertise, to develop an exciting portfolio of Targeted Alpha Therapies. Targeted Alpha Therapies hold incredible promise however their development has been hamstrung by a lack of radioisotope supply. Together with the team at AdvanCell, we look forward to writing a new chapter in oncology, to target large patient populations with significant unmet needs.”
Mr Aiudi has been appointed to the Board of AdvanCell, joining Mr Adamovich, Bill Ferris AC, co-founder of CPE Capital, Adrian “Adi” Patterson, former Australian Nuclear Science and Technology Organisation (ANSTO) CEO and Kevin Cameron, CEO of Ionetix.
Bill Ferris AC, Chair remarked, “Our executive team has articulated a credible pre-clinical and clinical pathway for the delivery of the Company’s novel Targeted Alpha Therapies. Having successfully developed the manufacturing platform essential for the reliable and scalable supply of isotopes, the Company is on schedule with its pre-clinical work and is now moving into first-in-human trials. AdvanCell is on track to become a leading radiopharmaceutical company with a platform technology enabling novel cancer treatments.”
About AdvanCell
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au
About Morningside
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside partners with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005846/en/
Contact information
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vecima Partners with AXING AG to Deliver Entra ® DAA Solutions to Cable Operators in Germany8.5.2024 13:30:00 CEST | Press release
Vecima Networks Inc. (TSX: VCM) today announced it has signed an agreement with AXING AG, a provider of telecommunications products and services in Germany, to serve as a reseller of Vecima’s industry-leading Entra® Distributed Access Architecture (DAA) product portfolio, including the Entra SC-1D Remote MACPHY Device and the Entra EN2112 Remote PHY Access Node. Vecima's Entra SC-1D Remote MACPHY Device, a cornerstone of the Entra DAA family, is specifically designed for DAA applications, enabling operators to transition their networks toward a more distributed, efficient, and scalable architecture. The SC-1D simplifies network design and enhances operational efficiency by moving the MAC and PHY layer functions closer to the network edge, thereby reducing latency and increasing bandwidth availability. The Entra EN2112 Remote PHY Access Node is a high-density, compact, two-port node that’s interoperable with third-party converged cable access platform (CCAP) cores and vCMTS (virtual cab
Silver Lake Closes $20.5 Billion Fundraise for SLP VII8.5.2024 13:00:00 CEST | Press release
Silver Lake, the global leader in technology investing, today announced a final close on Silver Lake Partners VII at $20.5 billion in capital commitments, topping its prior flagship fund. In aggregate over the past five years, Silver Lake has raised $47 billion behind the firm’s singular mission of creating value by partnering with exceptional founders and management teams to build and grow great companies driven by technology at scale. “We are deeply grateful to each of our investors, new and returning, for the confidence they place in Silver Lake,” said Co-Chief Executive Officers Egon Durban and Greg Mondre on behalf of the firm’s Managing Partners. “We are similarly appreciative of the truly special management teams we are so fortunate to work with – the world’s best – with whom we have cultivated successful and winning relationships based on deep engagement and trust through multiple cycles of technology investing at scale.” “As the promises and risks of the AI era accelerate, our
Eaton to supply innovative ELocker differential system to leading electrified vehicle manufacturer8.5.2024 12:30:00 CEST | Press release
Intelligent power management company Eaton today announced it has been selected by a leading manufacturer of electrified vehicles to supply a unique ELocker® differential system for use on a new plug-in electric hybrid (PHEV) SUV. Unlike traditional PHEVs, which use an electric motor and internal combustion engine to power all the drive wheels, the new model leverages an electric motor to power the rear wheels and an electric motor or an optional internal combustion engine (ICE) driving the front wheels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508868697/en/ Eaton has been selected by a top electrified vehicle manufacturer to supply a specialized ELocker® differential system. (Photo: Business Wire) “The ELocker had to be designed to be compatible with fluid in an electric drive, which is lighter and has a lower viscosity than axle and transmission oils,” said Mark Kramer, business unit director, ePowertrain, Eaton’s
Lubrizol Showcases LIPOFER™ Microencapsulation Technology, Introduces New EU Food-Grade Approval for Carbopol® Polymers at Vitafoods Europe 20248.5.2024 12:30:00 CEST | Press release
The Lubrizol Corporation, a specialty chemical company whose science delivers sustainable solutions to advance mobility, improve well-being, and enhance modern life, will showcase its LIPOFER™ microcapsules that deliver iron with optimum performance at Vitafoods Europe. LIPOFER™ microcapsules are designed with a combination of cutting-edge technologies that deliver iron in an optimized way, overcoming issues such as iron’s off-taste, reactivity, interaction with other ingredients, and color change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508166830/en/ LIPOFER is developed to cater to the growing demand for science-based products that meet the sensory needs of consumers. (Photo: Business Wire) The technology enhances iron absorption with low gastric irritation and provides a pleasant taste that encourages consumers to stick to recommended daily intakes. LIPOFER is developed to cater to the growing demand for science
Cardano Foundation Names Giorgio Zinetti as Chief Technology Officer8.5.2024 12:26:00 CEST | Press release
The Cardano Foundation, the Swiss-based not-for-profit organization tasked with advancing Cardano as a public digital infrastructure across a wide range of industries, today announced the appointment of Giorgio Zinetti as its Chief Technology Officer (CTO). In this role, he will be the technical leader for the Foundation, playing a key role in scaling the growing pipeline of Cardano Foundation projects and products, plus maximizing the open source model to deliver the next generation of enterprise blockchain technology. Commenting on the appointment, Frederik Gregaard, CEO of the Cardano Foundation, stated: “Adding Giorgio to the executive team as our first CTO is a significant milestone for the Foundation that marks our commitment to technical excellence. His experience and expertise will support us in our mission to increase the adoption of blockchain solutions that can both enhance the nature of trust and be the basis for new applications, industries, and economies.” The appointment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom